Eyeing the Next Stage
|
|
|
- かずし いざわ
- 5 years ago
- Views:
Transcription
1 Eyeing the Next Stage
2 Our Values CONTENTS At a Glance CEO CSR IMSJPM 2014 IMS Health IMS-JPM
3 Santen Pharmaceutical Co., Ltd. Annual Report
4 Our Vision % 50% Santen Pharmaceutical Co., Ltd. Annual Report 2014
5 P.10 CEO Santen Pharmaceutical Co., Ltd. Annual Report
6 Our 85.7% No.1 1 3, MR No.2 No ,487 P.30 4 Santen Pharmaceutical Co., Ltd. Annual Report 2014
7 Advantage mL P.18 P Santen Pharmaceutical Co., Ltd. Annual Report
8 At a Glance 127, % % 25.5% 43.5% % P.30 P.36 10, % % DMARDs 2 EN 3.8% P.34 6, % % FX 0.3% P.35 2, % 19.3% P.36 1, % 8.8% DMARDs IMS-JPM Santen Pharmaceutical Co., Ltd. Annual Report 2014
9 At a Glance COSOPT COSOPT COSOPT PF TRUSOPT TRUSOPT PF TIMOPTIC TIMOPTIC PF TIMOPTIC-XE SAFLUTAN TAPTIQOM Santen Pharmaceutical Co., Ltd. Annual Report
10 / ,594 29,640 18,723 18,826 14,123 1,315 3, ,812 30,739 21,333 19,797 13,221 1,651 2, ,416 26,732 17,161 16,966 17,225 3,281 2, ,066 24,681 16,521 21,729 16,720 3,609 3, ,663 27,414 17,109 25,379 19,040 4,786 3,927 $ 1,444, , , , ,998 46,502 38, % , , , , , , , , , ,811 $ 2,245, ,756, % (29.7) EPS , , , , , $ % % % % ROE% DOE% , , , , , ,500 1,487 % % ,191 1,144 1,106 1, Santen Pharmaceutical Co., Ltd. Annual Report 2014
11 EPS % TRC105 DE EPS 2,000 1,000 0 ROE 1, , , , , % ROE DOE % DOE DOE 5.1 ROE 1 DOE 6 % P.50 P.54 P Santen Pharmaceutical Co., Ltd. Annual Report
12 CEO President and CEO s Message CEO 10
13 %1, % % VEGF Ikervis : : DE QOL Quality of Life % CEO Santen Pharmaceutical Co., Ltd. Annual Report
14 ROE ,210 1, % 10.2% Santen Pharmaceutical Co., Ltd. Annual Report 2014
15 % CEO , ROE % % Santen Pharmaceutical Co., Ltd. Annual Report
16 ,050 1,450 1, , ,864 1, Santen Pharmaceutical Co., Ltd. Annual Report 2014
17 20201 CEO Santen Pharmaceutical Co., Ltd. Annual Report
18 COSOPT COSOPT PF TRUSOPT TRUSOPT PF TIMOPTIC TIMOPTIC PF TIMOPTIC-XE SAFLUTAN TAPTIQOM Santen Pharmaceutical Co., Ltd. Annual Report 2014
19 CSR CSR CSR CSR CSR 3 ISO CSR CSR 2020 CSR CSR 2. ISO NGO CEO Santen Pharmaceutical Co., Ltd. Annual Report
20 No.1 Expanding Operations in Asia 2020 No.1 18 Santen Pharmaceutical Co., Ltd. Annual Report 2014
21 2020 No % % % 1232% No.1 * % * wth in the Asian Market 25.5% Santen Pharmaceutical Co., Ltd. Annual Report
22 1 Expanding 22.3 % 30.2% GSP 2 GSP Good Supply Practice 20 Santen Pharmaceutical Co., Ltd. Annual Report 2014
23 200 MR 10 MR M essage % No.2 QOL No.1 Santen Pharmaceutical Co., Ltd. Annual Report
24 No No Santen Pharmaceutical Co., Ltd. Annual Report 2014
25 M essage No.1 QOL QOV Quality of Vision: QOL Quality of Life No.1 28 APAO Santen Pharmaceutical Co., Ltd. Annual Report
26 CEO QOL Quality of Life 3 POC Santen Pharmaceutical Co., Ltd. Annual Report 2014
27 Ikervis TRACONTRC105 DE DE-122VEGF 150 DE SAKURA Ikervis 1. Proof of Concept Study Assessing double-masked Uveitis treatment Standardization of Uveitis Nomenclature Working Group DE-109 SAKURA Trace 0 SUN 7 0SAKURA DE Santen Pharmaceutical Co., Ltd. Annual Report
28 1 2 3 DE-089 Merck Sharp & Dohme Corp DE DE DE-117 2b DE DE-090 MSD DE-109 DE-120 1/2a Santen Pharmaceutical Co., Ltd. Annual Report 2014
29 DE DE NMDA MSD DE DE DE-120 VEGF PDGF /2a DE DE-117 EP b DE Santen Pharmaceutical Co., Ltd. Annual Report
30 1 2 3 Cyclokat Vekacia Catioprost Cortiject 1/ POC Proof of Concept 28 Santen Pharmaceutical Co., Ltd. Annual Report 2014
31 Cyclokat M essage Vekacia 3 Catioprost F2 Cortiject DE DE DE DE-109 M Santen Pharmaceutical Co., Ltd. Annual Report
32 , % %3, %1, % ,200 1, , ,000 2, ,013 2,734 2,474 2,549 2, VEGF 30 Santen Pharmaceutical Co., Ltd. Annual Report 2014
33 11.5% % % % P2Y TOPICS Osaka Study Osaka Study Osaka Study 65% Osaka Study 2013 Santen Pharmaceutical Co., Ltd. Annual Report
34 10.5%1,047 35% % % % VEGF 52.6% VEGF Santen Pharmaceutical Co., Ltd. Annual Report 2014
35 % 1.5% VEGF VEGF % VEGF % % Santen Pharmaceutical Co., Ltd. Annual Report
36 9.7% % % , % H1 H1 DMARDs 1 5.5% H1 EN % Santen Pharmaceutical Co., Ltd. Annual Report 2014
37 DMARDs 38.4% DMARDs EN QOL Quality of Life , % % EN 1987 EN1995 EN QOL FX FX 0.6% PC 2004 Santen Pharmaceutical Co., Ltd. Annual Report
38 , % , % % % 43.5% % % % % 36 Santen Pharmaceutical Co., Ltd. Annual Report 2014
39 MR MR No.1 TOPICS 34 WOC2014 TOKYO WOC2014 TOKYO ,000 WOC2014 TOKYO2020 Santen Pharmaceutical Co., Ltd. Annual Report
40 CSR CSR QOL Quality of Life CSR CSR QO QOL L Quality of Life 38 Santen Pharmaceutical Co., Ltd. Annual Report 2014
41 CSR CSR CSR 3 ISO CSR CSR CSR CSR CSR 1. ISO NGO CSR CSR CSR CSR CSR 7 CSR Plan Do Check Action PDCA KPI CSR CSR CSR CSR Plan P CSR Action 2 3 Check Do KPI A 1 C D CSR NPO NGO Santen Pharmaceutical Co., Ltd. Annual Report
42 CSR 3 MR CSR Santen Pharmaceutical Co., Ltd. Annual Report 2014
43 CO 2 t-co ISO ,000 9,000 CSR NGO CSR Santen Pharmaceutical Co., Ltd. Annual Report
44 Corporate Governance CSR CEO Santen Pharmaceutical Co., Ltd. Annual Report 2014
45 Santen Pharmaceutical Co., Ltd. Annual Report
46 44 Santen Pharmaceutical Co., Ltd. Annual Report CSR 4 3
47 BCM PDCA 1 IR P PlanD DoC CheckA Action IR Santen Pharmaceutical Co., Ltd. Annual Report
48 Message Santen Pharmaceutical Co., Ltd. Annual Report 2014
49 CEO COO 20 CEO Santen Pharmaceutical Co., Ltd. Annual Report
50 CEO CSR 48 Santen Pharmaceutical Co., Ltd. Annual Report 2014
51 Santen Pharmaceutical m Co., Ltd. Annual Report
52 2 98.0% 24.7%1, % %1, %1, % 25.5%1, % FX 0.3% % % , , , , ,396 98, ,251 9, ,611 1, ,455 6,474 (0.3) 2,950 2, ,678 2, , , %1, ,600 1,487 1,106 1,108 1,144 1,191 EN % Santen Pharmaceutical Co., Ltd. Annual Report 2014
53 40.0% % % % % % % % % % 11.1% %18.4% 11.5% 1EPS Santen Pharmaceutical Co., Ltd. Annual Report
54 1EPS % % ,311 6 ROA 8.3% 7.4% 1, %67.5% ROA ROA % 2, ,311 1,988 1,996 1,848 1, , %78.2% 1 9.6% ,189.50ROE 10.0%9.9% ROE ROE % 2, ,808 1,645 1,648 1,561 1, , , Santen Pharmaceutical Co., Ltd. Annual Report 2014
55 ROE DOE DOE5% 1100 DOE 4.8% DOE5.1% 1DOE 1 DOE % ,958 9,943 16, (6,695) (4,596) (2,099) (7,953) (21,557) 13,604 72,397 59,797 12,600 Santen Pharmaceutical Co., Ltd. Annual Report
56 PL % % XE EN 54 Santen Pharmaceutical Co., Ltd. Annual Report 2014
57 10 70% PL Santen Pharmaceutical Co., Ltd. Annual Report
58 ,858 92,696 98, ,486 31,859 33,710 34,535 35,484 43,475 40,004 42,868 44,590 14,524 18,982 20,995 20, ,775 18,436 20,342 21,039 7,454 7,413 7,319 7,891 6,321 11,023 13,023 13,148 3,226 4,907 2,106 3,556 4,521 4,750 4,824 4,761 11,853 12,620 13,971 13, , , , , ,196 6,619 20,879 14,959 5,246 (2,907) (1,330) (5,846) (12,122) (12,712) (5,900) (5,691) % ,231 82,735 93, ,820 37,237 32,676 30,395 30, , , , ,099 12,686 6,882 5,614 5, , , , ,587 ROE% ROA% % % PER DOE% ,963 86,659 86,751 86,825 2,335 2,308 2,312 2, Santen Pharmaceutical Co., Ltd. Annual Report 2014
59 , , , , , , ,663 $1,444,456 36,513 35,947 34,710 34,437 35,385 41,501 58, ,564 46,510 50,178 46,244 45,636 52,299 52,884 63, ,529 20,371 15,494 29,640 30,739 26,732 24,681 27, , ,483 15,824 28,610 31,074 27,791 25,592 26, ,302 7,832 5,701 9,887 9,741 10,630 9,071 9,784 95,063 12,651 10,123 18,723 21,333 17,161 16,521 17, ,239 3,151 2,953 1,315 1,651 3,281 3,609 4,786 46,502 4,593 4,210 3,421 2,976 2,949 3,291 3,927 38,155 12,942 18,458 14,123 13,221 17,225 16,720 19, , $ , , , , , , , ,468 11,849 26,110 17,768 21,483 9,943 25,958 $ 252,218 (2,083) (5,619) (829) (7,676) (10,273) (4,596) (6,695) (65,049) (11,415) (11,373) (6,753) (1,570) (8,559) (21,557) (7,953) (77,276) , , , , , , , , , ,006 $1,515,803 29,849 28,665 26,574 24,957 25,523 27,420 27, , , , , , , , ,106 2,245,489 5, , , , , , , ,811 1,756, ,867 86,916 86,992 87,053 87,147 82,469 82,583 2,483 2,690 2,756 2,867 3,053 3,050 3,072 Santen Pharmaceutical Co., Ltd. Annual Report
60 ,397 59,797 $ 703, ,225 2,094 41, ,571 51,616 43, ,511 (4) (2) (36) 52,082 43, , ,031 20, , ,346 1,880 22,796 4,925 4,024 47, , ,583 1,515, ,266 8,241 80,315 45,033 42, ,554 13,347 11, ,684 12,910 11, , , ,455 7,937 80,659 77, ,710 (53,030) (50,089) (515,262) 27,629 27, , ,740 18, ,229 6,298 5,936 61,193 8,357 6,768 81,202 1,930 1,420 18, ,488 4,460 53,327 3,658 2,880 35,536 47,471 39, , , ,641 $2,245, Santen Pharmaceutical Co., Ltd. Annual Report 2014
61 ,270 9,266 $ 138, ,696 9,868 94,207 5,459 4,202 53, ,170 3,039 79,379 1, ,568 39,094 27, , , ,401 52, ,796 2,269 27, , ,797 1,480 1,011 14,376 10,802 7, , ,896 34, , ,000, ,000,000 82,582, ,469,103 7,264 7,081 70, ,959 7,775 77, , ,002 1,555,728 2, (9) (2) (90) 175, ,856 1,703, ,036 1,920 39,214 2,574 (2,968) 25,010 (1,129) (10,966) 5,481 (1,048) 53, , , ,132 1,760, , ,641 $2,245,489 Santen Pharmaceutical Co., Ltd. Annual Report
62 , , ,416 $1,444,456 58,104 41,501 35, ,564 90,559 77,565 79, ,892 63,145 52,884 52, ,529 27,414 24,681 26, , , ,438 (223) (2,163) (6) (7) (23) (55) , (1,381) (13,415) 10 (94) (19) (916) (41) (403) 26,893 25,592 27, , ,763 7,908 9, ,291 (1,979) 1, (19,228) 9,784 9,071 10,630 95,063 17,109 16,521 17, ,239 17,109 16,521 17, ,239 17,109 16,521 17, , ,143 1, ,816 5,542 3,339 (689) 53, ,686 8,270 5,208 (195) 80,346 25,379 21,729 16, ,585 25,379 21,729 16,966 $ 246, $ Santen Pharmaceutical Co., Ltd. Annual Report 2014
63 ,615 7, ,578 (2) (443) (5,618) (8,709) 17,161 (2) (689) ,695 8, ,030 (4) 51 (6,307) (8,469) 16,521 (13,738) (660) (13,080) 13,740 1,869 3,339 (23) ,081 7, ,002 (2) 1,920 (2,968) (1,714) 7,081 7, ,230 (2) 1,920 (2,968) (1,714) (8,250) 17,109 (7) ,116 5, ,264 7, ,116 (9) 4,036 2,574 (1,129) $68,800 $75,547 $1,467,178 $ (25) $18,656 $(28,834) $ $3,155 2,214 (16,652) 68,800 75,547 1,469,392 (25) 18,656 (28,834) (16,652) 3,155 1,781 1,780 (80,161) 166,239 (65) ,558 53,844 5, $70,581 $77,327 $1,555,728 $ (90) $39,214 $ 25,010 $(10,966) $3,879 Santen Pharmaceutical Co., Ltd. Annual Report
64 Santen Pharmaceutical Co., Ltd. Annual Report ,893 25,592 27,791 $261,302 2,914 2,657 2,787 28,314 1, ,841 (474) (42) (4,605) ,381 13, ,045 (602) (522) (529) (5,848) (7,672) (5,560) 1,037 (74,547) 1,650 (2,589) (3,294) 16,033 4,927 1,170 2,034 47,875 1,970 (1,790) 52 19,136 32,413 19,786 30, , ,972 (3) (3) (17) (28) (7,067) (10,372) (9,268) (68,658) 25,958 9,943 21, ,218 (4,786) (3,609) (3,281) (46,502) (4,221) (4,883) (2,420) (41,008) ,096 (734) (807) (1,783) (7,135) 2,520 4,680 7,632 24,483 (10,804) (3) (7) (26) 3 8 (6) (18) (1) (65) (6,695) (4,596) (10,273) (65,049) (7) (13,763) (2) (66) (8,247) (8,469) (8,706) (80,134) ,923 (7,953) (21,557) (8,559) (77,276) 1, (98) 12,526 12,600 (15,238) 2, ,419 59,797 75,035 72, ,006 72,397 59,797 75,035 $703,425
65 ,171 $ 6,251 6,195 (340) (2,320) (2) 10,955 (32) (119) 10,804 $ Santen Pharmaceutical Co., Ltd. Annual Report
66 a b c d e ,79127, ,173 1,04210,123 1,05710, Santen Pharmaceutical Co., Ltd. Annual Report 2014
67 Santen Pharmaceutical Co., Ltd. Annual Report
68 ,537 84,368 87, ,790 84,500 87, Santen Pharmaceutical Co., Ltd. Annual Report 2014
69 , , , ,96657,969 1,71416, , Santen Pharmaceutical Co., Ltd. Annual Report
70 ,316 2, $ 32,218 (57) 3,316 2, ,218 (1,173) (1,027) (330) (11,402) 2,143 1, ,816 5,542 3,339 (689) 53, , , ,799 (321) (3,113) 585 5,686 8,270 5,208 (195) $ 80, Novasorb* Cyclokat Novasorb * % 100% , , , Santen Pharmaceutical Co., Ltd. Annual Report 2014
71 10 5 1,171 12,446 13, ,320 2, , Santen Pharmaceutical Co., Ltd. Annual Report
72 ,397 72,396 (1) 59,797 59,797 (0) 52,085 52,085 43,841 43, ,112 4,111 (1) 4,218 4,218 (0) 21,235 21,235 15,477 15,477 (14,270) (14,270) (9,266) (9,266) (9,696) (9,696) (9,868) (9,868) (8,170) (8,170) (3,039) (3,039) 2014 $ 703,425 $ 703,420 $ (5) 506, ,082 : 1,094 1,094 39,954 39,947 (7) 206, ,321 (138,655) (138,655) (94,207) (94,207) (79,379) (79,379) Santen Pharmaceutical Co., Ltd. Annual Report 2014
73 $4, $4, ,397 59,797 $ 703,425 $ 52,085 43, ,082 : ,094 4,100 2,000 2,200 39, , ,724 2,200 $1,250,438 $ ,000 1, ,704 1, ,112 3,111 (1) 2,514 2,513 (1) 4,112 4,111 (1) 4,218 4,218 (0) : 2014 $ 9,718 $ 9,720 $ 2 30,236 30,227 (9) $39,954 $39,947 $(7) Santen Pharmaceutical Co., Ltd. Annual Report
74 ,244 16,597 6,353 12,012 15,061 3, ,776 4,638 (138) (84) 15,020 21,235 6,215 12,512 15,477 2, $ 99,532 $161,263 $61, ,409 45,058 (1,351) $145,941 $206,321 $60, , $ % 30 50% 72 Santen Pharmaceutical Co., Ltd. Annual Report 2014
75 ,222 16,703 $157, ,796 3,418 3,621 33,206 20,031 20,949 $194, $ 12 $ 0 $ $ 4, ,124 1,222 1,275 $11, Santen Pharmaceutical Co., Ltd. Annual Report
76 $ $ $ $ $ $ Santen Pharmaceutical Co., Ltd. Annual Report 2014
77 % (17,372) 11,053 (6,319) 2,655 (249) (3,913) (208) (198) ,312 2, % 2.00% 2.00% 2.00% * * Santen Pharmaceutical Co., Ltd. Annual Report
78 % i ,372 $168,789 (353) (3,431) 17, ,358 1,069 10, ,938 (190) (1,844) (916) (8,903) ,217 $167,281 ii ,052 $107, , , ,251 (351) (3,415) ,816 $114, Santen Pharmaceutical Co., Ltd. Annual Report 2014
79 iii ,036 $165,523 11, ,808 5,220 50, ,758 5,401 52,473 5,401 52,473 5,401 52,473 iv ,069 $10, ,938 (222) (2,159) 269 2,612 1,315 $12,775 v $8, $8,799 vi ,749 $16,997 1,749 $16,997 Santen Pharmaceutical Co., Ltd. Annual Report
80 vii 1. 34% 50% 16% 100% 35% viii % 2.0% 3. 1,19011, % 25% 10% ,551 15,0741, , ,938, ,080 13, ,129 40, Santen Pharmaceutical Co., Ltd. Annual Report 2014
81 , , , , , ,700 99, , ,200 78, , Santen Pharmaceutical Co., Ltd. Annual Report
82 ,600 30, , ,500 91, , ,000 30,600 5,800 3, ,900 30, , ,700 88, ,100 82, ,500 70,800 38,900 2, ,000 27,800 18,300 2, ,500 43,000 20, ,315 3,230 3,170 2,920 2,734 4,747 4,425 4,425 4,506 4, ,050 2,715 2,480 1,743 1,176 4,446 4,500 4,648 4,525 4,555 * * ,040184,99816,72017, Santen Pharmaceutical Co., Ltd. Annual Report 2014
83 % 37.9% 40.4% % 37.9% 40.4% (0.3) 0.9 (0.5) (0.5) 2.7 (5.0) (5.1) (6.2) (1.6) (0.7) % 35.4% 38.2% ,294 5,842 $70,873 3,298 32,046 1, ,330 1,116 1,037 10, , , , , ,028 1,837 29,417 18,270 14, ,514 (8,188) (6,764) (79,559) 10,082 7,428 97,955 (2,786) (2,256) (27,065) (2,225) (1,057) (21,616) (11) (18) (109) (22) (26) (213) (5,044) (3,357) (49,003) 5,038 4,071 $48,952 Santen Pharmaceutical Co., Ltd. Annual Report
84 ,346 1,880 $ 22,796 5,488 4,460 53,327 (2,796) (2,269) (27,171) 5,038 4,071 $ 48, % % % % 35.48% , Santen Pharmaceutical Co., Ltd. Annual Report 2014
85 ,713 2, , , (124) 145,713 3, ,787 (124) 148,663 27,828 (414) 27,414 27, ,283 3, ,749 89, ,106 2, ,914 2,914 1,013 1,013 1,013 3, ,870 3, ,810 2, , , (114) 116,810 2, ,180 (114) 119,066 25,354 (673) 24,681 24, ,546 2, ,990 76, ,641 2, ,657 2, , ,243 5, ,846 2, , , (113) 111,846 2, ,529 (113) 114,416 26, ,732 26, ,535 2, ,661 90, ,801 2, ,787 2, , ,971 15,971 Santen Pharmaceutical Co., Ltd. Annual Report
86 $1,415,789 $28,667 $1,444,456 $ $1,444,456 1,196 1,196 (1,196) 1,415,789 29,863 1,445,652 (1,196) 1,444, ,381 (4,018) 266, ,363 1,343,598 33,675 1,377, ,216 2,245,489 27, ,314 28,314 9,841 9,841 9,841 37, ,603 37, ,396 98,981 93,620 $1,237,814 10,251 9,874 9,987 99,605 1,611 1,481 3,642 15,649 6,455 6,474 4,597 62,721 2,678 2,246 2,558 26, , , , ,416 $1,444, Santen Pharmaceutical Co., Ltd. Annual Report 2014
87 , ,712 95,374 $1,186,486 12,295 9,202 8, ,459 1, ,451 10,428 13,174 8,560 6, , , , ,416 $1,444,456 22,826 22,560 21,157 $ 221,785 2,106 2,597 2,245 20, ,259 2,053 1,553 1,486 19,944 27,629 27,420 25,523 $ 268, ,546 25,486 23,297 $316,230 26,334 21,716 20, , $ $ , $ 9,841 1, $ 9,841 6,298 5,936 $61,193 6,298 5,936 $61,193 Santen Pharmaceutical Co., Ltd. Annual Report
88 Merck & Co., Inc UFJ 2. Merck & Co., Inc... Kenneth C. Frazier. 1, , COSOPT, COSOPT PF, TRUSOPTT, TRUSOPT PF, TIMOPTIC, TIMOPTIC PF, TIMOPTIC XE, SAFLUTAN, T APTIQOM , Santen Pharmaceutical Co., Ltd. Annual Report 2014
89 1 CEO % CEO Santen Pharmaceutical Co.,Ltd. Annual Report 2014Internal Control Report Santen Pharmaceutical Co., Ltd. Annual Report
90 Merck & Co., Inc KPMG AZSA LLC Santen Pharmaceutical Co., Ltd. Annual Report 2014Independent Auditor s Report 88 Santen Pharmaceutical Co., Ltd. Annual Report 2014
91 URL A TEL IR ir@santen.co.jp ,264 7, UFJ TEL ,0721,878 82,582, % 0.0% 10 5, % 45.5% 92.1% 9.6% 0.9% 0.0% 0.8% 0.4% 1.5% 5.2% 5, , , , UFJ 2, , , GIC PRIVA TE LIMITED 1, , ,000 4,500 3,000 1,500 0 TOPIX 09/4 10/4 11/4 12/4 13/4 14/4 12,000 9,000 6,000 3, /4 10/4 11/4 12/4 13/4 14/ ,195 3,445 3,655 5,050 6,150 2,694 2,731 2,778 3,330 4, Santen Pharmaceutical Co., Ltd. Annual Report
92 TEL FAX TEL FAX Niittyhaankatu 20, P.O. Box 33, FIN Tampere, Finland TEL FAX TEL FAX TEL FAX Santen Pharmaceutical Co., Ltd. Annual Report 2014
93 A TEL FAX TEL FAX Santen Holdings U.S. Inc Powell Street, Suite 1600, Emeryville, California 94608, U.S.A. Santen Inc Powell Street, Suite 1600, Emeryville, California 94608, U.S.A. TEL FAX Advanced Vision Science, Inc Thornwood Drive, Goleta, California 93117, U.S.A. TEL FAX Santen Holdings EU B.V. Herikerbergweg 238, 1101CM Amsterdam Zuidoost, Netherlands Santen Oy Niittyhaankatu 20, P.O. Box 33, FIN Tampere, Finland TEL FAX Santen S.A.S. 1 rue Pierre Fontaine, Genavenir IV, F Evry cedex, France TEL: FAX: Santen GmbH Erika-Mann-Strasse Munchen, Germany TEL FAX SantenPharma AB Solna torg 3, SE Solna, Sweden TEL FAX Santen Pharmaceutical (China) Co., Ltd TEL FAX Santen Pharmaceutical Korea Co., Ltd. KCUBE Tower 3F, 35, Yeoksam-ro 25-gil, Yeoksam-dong, Gangnam-gu, Seoul, , Korea TEL FAX Taiwan Santen Pharmaceutical Co., Ltd TEL FAX Santen India Private Limited No. 216, Raheja Chambers, 12 Museum Road, Bangalore , India TEL: FAX: Santen Pharmaceutical Asia Pte.Ltd. One Raffles Place, Level 24 Tower 1, 1 Raffles Place , Singapore TEL FAX W3-1206B TEL FAX Unit 1406, Fl.14, Empress Tower, Hai Ba Trung, Dakao Ward, District 1, HCMC, Vietnam TEL FAX Santen Pharmaceutical Co., Ltd. Annual Report
94 92 Santen Pharmaceutical Co., Ltd. Annual Report FX EN 1999 XE FX NE P
95 ISO14001 SAIN % E AL i 2009 FX V VEGF PC Santen Pharmaceutical Co., Ltd. Annual Report
96 Printed in Japan
CONTENTS CEO CSR 3 31 IMSJPM 213 IMS Health IMS-JPM
Eyeing Further 213 213 3 Specialization CONTENTS 1 2 4 6 12 18 2 24 3 32 36 4 41 77 78 8 CEO CSR 3 31 IMSJPM 213 IMS Health IMS-JPM 28.4-213.3 1 1. 189 189 12 P.12 P.24 8.3% 2 1 No.2 39.7% 5.4% No.2 19.1%
80% No.1 3... 1... 2... 5... 5... 9... 13... 14... 22... 22... 23... 24... 26... 27... 53... 54
2005 2005 3 Looking ahead 80% No.1 3... 1... 2... 5... 5... 9... 13... 14... 22... 22... 23... 24... 26... 27... 53... 54 20052004 3 2005 3 2004 3 2005/2004 2005 3... 92,696 89,858 3.2% $ 863,175... 18,982
8% No
Our vision... 24 24 3 8% No.1 3... 4 23-25... 6... 6... 8... 12... 14... 15... 16... 24... 25... 26... 28... 29... 53... 54... 55 for growth Santen Annual Report 24 1 for the future 2 Santen Annual Report
* Contents 1 2 CEO 4 CEO 5 : Reaching Out Globally 9 13 120 14 16 19 20 24 25 25 26 28 30 31 61 62 63 3 31 IMSJPM MIDAS 2006.1-2010.3
2010 for the Future Reaching Out 2010 2010 3 * Contents 1 2 CEO 4 CEO 5 : Reaching Out Globally 9 13 120 14 16 19 20 24 25 25 26 28 30 31 61 62 63 3 31 IMSJPM MIDAS 2006.1-2010.3 3 31 2010 2009 2010/2009
4% P % 11.1%1, % %1, %1, % 3.5%1, % %1, % Santen Ph
Financial Section 11 5 54 56 58 59 6 63 http://www.santen.co.jp/ja/ir/document/securities.jsp Santen Pharmaceutical Co., Ltd. Annual Report 215 49 4% 215 3 214 3 P.8 2 98.4% 11.1%1,592 62 12.6% 25 69 1.6%1,618
2004 3 1963 1 2 4 2004 MISUMI It s about TIME QCT 8 12 CSR 14 16 17 6 18 19 24 39 40
2004 2004 3 MISUMI It s about TIME 2004 3 1963 1 2 4 2004 MISUMI It s about TIME QCT 8 12 CSR 14 16 17 6 18 19 24 39 40 MISUMI Corporation ANNUAL REPORT 2004 2003 32004 3.................................................
1) IT IR CSR 120 DAIWA SECURITIES GROUP ANNUAL REPORT 2010
p120 p126 p130 p131 p133 DAIWA SECURITIES GROUP ANNUAL REPORT 2010 119 1) 2010 7 1 IT IR CSR 120 DAIWA SECURITIES GROUP ANNUAL REPORT 2010 121 DAIWA SECURITIES GROUP ANNUAL REPORT 2010 CEO COO SMBC PI
PREFACE: The Origins of Quality A I D A E n g i n e e r i n g, LT D.
PREFACE: The Origins of Quality A I D A E n g i n e e r i n g, LT D. Manufacturing In the Age of The Environment NS1-1500(D) +LFL 200 188 100 wh 97 1 1.67 2 100 kw/h A n n u a l R e p o rt 2 0 1 0 1 PREFACE:
13
Pharmaceutical Segment 12 13 14 Pharmaceutical Segment 15 16 Pharmaceutical Segment 17 GERMANY CHINA JAPAN U.S.A. KOREA SINGAPORE 18 Pharmaceutical Segment 19 20 Pharmaceutical Segment 21 22 Pharmaceutical
THE INTAGE WAY SDI 1964 SCI CONTENTS FEATURE 18 FEATURE INTAGE HOLDINGS Inc.
Renovation and Innovation 2015 201532 55 THE INTAGE WAY 1960 196032 507 SDI 1964 SCI 1970 1960 1973 CONTENTS 02 04 06 12 12 14 15 16 FEATURE 18 FEATURE INTAGE HOLDINGS Inc. POS 20153 439 2015 2000 2001
Contributes to The Health of Individuals Worldwide
ANNUAL REPORT 2008 Annual Report 2008 Our Contribution to Financial and Social Responsibility Contributes to The Health of Individuals Worldwide 2 4 10 16 17 20 22 29 30 32 37 38 40 47 54 64 66 70 102
これわかWord2010_第1部_100710.indd
i 1 1 2 3 6 6 7 8 10 10 11 12 12 12 13 2 15 15 16 17 17 18 19 20 20 21 ii CONTENTS 25 26 26 28 28 29 30 30 31 32 35 35 35 36 37 40 42 44 44 45 46 49 50 50 51 iii 52 52 52 53 55 56 56 57 58 58 60 60 iv
パワポカバー入稿用.indd
i 1 1 2 2 3 3 4 4 4 5 7 8 8 9 9 10 11 13 14 15 16 17 19 ii CONTENTS 2 21 21 22 25 26 32 37 38 39 39 41 41 43 43 43 44 45 46 47 47 49 52 54 56 56 iii 57 59 62 64 64 66 67 68 71 72 72 73 74 74 77 79 81 84
これでわかるAccess2010
i 1 1 1 2 2 2 3 4 4 5 6 7 7 9 10 11 12 13 14 15 17 ii CONTENTS 2 19 19 20 23 24 25 25 26 29 29 31 31 33 35 36 36 39 39 41 44 45 46 48 iii 50 50 52 54 55 57 57 59 61 63 64 66 66 67 70 70 73 74 74 77 77
untitled
i ii iii iv v 43 43 vi 43 vii T+1 T+2 1 viii 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 a) ( ) b) ( ) 51
2
1 2 3 4 5 6 7 8 9 10 I II III 11 IV 12 V 13 VI VII 14 VIII. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 _ 33 _ 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 VII 51 52 53 54 55 56 57 58 59
かんたん操作ガイド
1-2 i ii iii iv v vi vii viii 1Chapter 1-1 1-2 1-3 1-4 1-5 1-6 1-7 1 3 2 4 1-8 1-9 1-10 2Chapter 2-1 2-2 Check! 2-3 Point 2-4 Point 2-5 Point 2-6 1 a a b c 2 a b c b 2-7 c 5 3 4 6 a 2-8 b b c b 7 a c a
ニコンレポート2016
NIKON REPORT 216 216 216 3 1 2171 19171 216 3Next 1 - Transform to Grow 6 216 2171215 1 http://www.nikon.co.jp/profile/museum/ ABOUT NIKON 2 4 6 BUSINESS STRATEGY 8 9 14 16 BUSINESS PERFORMANCE 18 22 216
,889 99, , , ,031 8,952 13,261 16,443 14,464 17,948 % ,037 8,848 10,927
2013 2013 3 3 313 31 2008 2009 2010 2011 2012 90,889 99,764 104,069 103,232 107,031 8,952 13,261 16,443 14,464 17,948 % 9.8 13.3 15.8 14.0 16.8 2,037 8,848 10,927 9,231 12,422 % 2.2 8.9 10.5 8.9 11.6 4,575
エクセルカバー入稿用.indd
i 1 1 2 3 5 5 6 7 7 8 9 9 10 11 11 11 12 2 13 13 14 15 15 16 17 17 ii CONTENTS 18 18 21 22 22 24 25 26 27 27 28 29 30 31 32 36 37 40 40 42 43 44 44 46 47 48 iii 48 50 51 52 54 55 59 61 62 64 65 66 67 68
untitled
2006 One Company 62,028372,669 WINWIN M&AOne Company 1997200610% 15%2010121,50010%ROE 11% 200532020063201231 2005.3 2006.3 2006.12 2006.12 % 92,492 9,373 10.1 6,105 2,290 3,524 3,956 2,944 5,636 105,665
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 () - 1 - - 2 - - 3 - - 4 - - 5 - 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
アニュアルレポート 2014
SoftBank Corp. ANNUAL REPORT 2014 053 The Fast Read CSR SoftBank Corp. ANNUAL REPORT 2014 054 The Fast Read CSR 2014 6 20 1981 9 1983 4 1986 2 1996 1 1996 7 2001 6 BB 2004 2 CEO 2004 7 2006 4 CEO 2006
サステナビリティ報告書
Living and Working together for the common good. 1 Canon Sustainability Report 2003 Canon Sustainability Report 2003 2 3 Canon Sustainability Report 2003 Canon Sustainability Report 2003 4 93 94 95 96
CSR ERX ERX
Corporate Report 2010 2010 3 100 1959 1 2 4 6 7 8 9 10 12 14 18 20 22 23 24 26 27 28 30 50 50 100 100 100 CSR 100 1960 1962 1 1969 1974 1985 1993 2003 ERX ERX 50 2009 Corporate Report 2010 1 50 100 50
大和ハウスグループ アニュアルレポート2009
CEO COO CFO 18 19 Dear Stakeholders Building a New Era with Heart 20 2008 4 2 3 Challenge 2010 2008 35.3% GDP 2008 1.1% 1 6,909 5 6 735 817.4% 398 5 535.0% 41 768.1% ROE 0.7%9.0% 1 24 22009 20207 9 1002055
<4D6963726F736F667420506F776572506F696E74202D208376838C835B83938365815B835683878393312E707074205B8CDD8AB78382815B83685D>
i i vi ii iii iv v vi vii viii ix 2 3 4 5 6 7 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
SC-85X2取説
I II III IV V VI .................. VII VIII IX X 1-1 1-2 1-3 1-4 ( ) 1-5 1-6 2-1 2-2 3-1 3-2 3-3 8 3-4 3-5 3-6 3-7 ) ) - - 3-8 3-9 4-1 4-2 4-3 4-4 4-5 4-6 5-1 5-2 5-3 5-4 5-5 5-6 5-7 5-8 5-9 5-10 5-11
businessreport_cover
41331 3 331 33193 28 Business Report 21.4.1 211.3.31 6727 533 31 183-871 11 12-176-417 http://www.sumitomotrust.co.jp/sta/retail/ service/daiko/index.html IR http://wacom.jp/jp/company/ 349-1148511 TEL48-78-1211FAX48-78-122
Kumagai09-hi-2.indd
CSR2009 CONTENTS 1 2 3 4 5 6 7 8 9 10 350 11 12 13 14 15 16 17 18 Do Check Action Plan 19 20 INPUT r r r r k k OUTPUT 21 22 Plan Action Check Do 23 24 25 26 27 28 16:50 7:30 8:00 8:30 9:30 10:00 18:00
Profile 1927 12 1958 1969 PT MANDOM INDONESIA Tbk 1996 11 2 1978 7 27 1984 7 1 2 3 6 8 8 10 12 14 16 20 22 24 28 30 31 32 34 35
MANDOM Corporation Annual Review 2005 Construct the Foundation for Next Growth Profile 1927 12 1958 1969 PT MANDOM INDONESIA Tbk 1996 11 2 1978 7 27 1984 7 1 2 3 6 8 8 10 12 14 16 20 22 24 28 30 31 32
http://www.softbank.co.jp/ The No.1 Name in Broadband ANNUAL REPORT 2003 Contents 2 4 The Reason why SOFTBANK is No.1 in the Broadband Market 12 13 54 55 21 1876 1941 1970 IT20 ADSL Yahoo! BB No.1 2003
1. 8. Value Chain 10. At a Glance
Annual Report 2007 1. 8. Value Chain 10. At a Glance 12. 14. 18. 23. 33. 41. 48. 49. 50. 51. HOUSING MARKET Market trends are not promising but there are many opportunities for our growth 1 () 128 127
i ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13
日立 統合報告書 2017 (2017年3月期)
MANAGEMENT & 2017 6 01 1972 Bharat Forge Limited 1983 1994 1997 2016 02 1991 Alcan Inc. 1996 1998 2002 CEO 2007 Anglo American plc. CEO 2013 4 2013 03 2002 2010 2013 2014 2015 2017 04 1993 Emerson Electric
アニュアルレポート 2013
050 CSR 2013 6 21 Director and President, SoftBank Holdings Inc. 1981 9 1983 4 1986 2 1996 1 1996 7 2001 6 BB 2004 2 CEO 2004 7 2006 4 CEO 2006 10 CEO 2007 6 CEO 1977 2 1984 10 1988 2 1993 4 1999 9 BB
NIKON REPORT2018
NIKON REPORT 218 218 218 3 Unlock the future with the power of light Unleashing the limitless possibilities of light. Striving to brighten the human experience. Focused, with purpose, on a better future
1) 2011 7 1 104
P104 P110 P114 P115 P117 103 1) 2011 7 1 104 22011 7 1 CEO COO CFO CRO CIO 105 1) 2011 7 1 106 22011 7 1 107 108 1) 2011 7 1 109 22011 7 1 2011 7 1 100-6755 1 9 1 03 5555-7555 060-8601 3 7 011 214-6111
1 1,200m ,482,620m 1 323,825m 1 205,988m 114,988m 60,000m 31,000m ,837m ,158,795m ,340m 1 48,006m 1 33,016m 1,125m
IV 39 7 10 167 1 3 9 2 10 79 1 1,200m 23 23 6 1 429 2,482,620m 1 323,825m 1 205,988m 114,988m 60,000m 31,000m 27 117,837m 3 2 426 2,158,795m 44 277,340m 1 48,006m 1 33,016m 1,125m 33,016m 4 14,990m 2 44
95 SMBC
94 CEO CIO S ( CEO ) 2002 6 26 95 SMBC 2002 6 26 2002 6 26 96 2002 7 1 97 2002 7 1 98 2002 7 1 100-8155 6 4 03 3243-2626 100-0011 2 2 03 3508-8111 102-0073 2 3 03 3221-9811 104-0028 8 1 03 3243-3811 104-0061
untitled
Change and Innovation 214 213 1 215 3 Change and Innovation 3 resilience 2 13 23 43 67 Overview 2 4 6 8 1 12 213 1 213 215 Management Strategy 14 16 Our Operations 24 26 28 3 32 34 36 4 42 CSR & Governance
Traditional View The Red that You ve never seen CYAN : 10 MAGENTA : 100 YELLOW : ADK VISION VI Visual Identity ADK ADK Active Red Ac
2014 2014 12 THE DIFFERENCE IN RED Traditional View The Red that You ve never seen CYAN : 10 MAGENTA : 100 YELLOW : 90 2013 ADK VISION 2020 2014 VI Visual Identity ADK ADK Active Red Active Red ADK BLACK
Corporate Philosophy Otsuka-people creating new products for better health worldwide
ANNUAL REPORT 2013 Corporate Philosophy Otsuka-people creating new products for better health worldwide 00 13 44 Contents 02 14 48 03 16 54 04 22 59 06 30 76 08 36 78 10 38 79 12 41 Group Structure ur
untitled
27.4.1 s 28.3.31 31 8515 Vol.24 June 28 Top Message 283 1 16 4 17 5 Topics 18 CSR 7 19 1 2 12 21 21 4,574,99 321,63274 1 3 Top Message 2 4,112 33 317 2825 7 64%5% ROA1.5% 5, 1, 15, 2, 25, 3, 25,225 25/3
1. 2. 3. 4. 5. Contents The Asahi Kasei History... 1... 4... 5 Growth Action 21... 6... 12 At a Glance... 14... 16... 32 CSR... 36... 38... 39... 7...
27 27 1. 2. 3. 4. 5. Contents The Asahi Kasei History... 1... 4... 5 Growth Action 21... 6... 12 At a Glance... 14... 16... 32 CSR... 36... 38... 39... 7... 72... 73 The Asahi Kasei History 1922 1931 199199
平成20年度内部評価実施結果報告書《本編》
10 11 12 13 14 15 16 17 Plan Do Check Action 1 2 3 4 146 13 20 43 44 45 62 104 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47
untitled
1 1 2 3 2 1 ( 0) 2000 00 3 4 Check Action Do Plan 5 6 14001 5000 5000 1000 1000 7 8 9 10 2004 0.1 0.1 0.0 0.0 0.0 15.3 483.5 0.4 11 12 13 14 http://kankyou.pref.shizuoka.jp/seikan/seikanindex.htm 15 16
18725 136 2008 3 4 6 8 10 16 18 24 40 41 6 42 43 54 59 75 76 77 CSR 30 34 38 200620072008 3 4.27,235 26.9635 1.68.8 ROE2.69.2 1234.0 1 2006 2007 2008 2008/2007 2008 670,957 694,594 723,485 +4.2% $7,220,409
-2-
-1- -2- -3- -4- -5- -6- -7- -8- 10-9- -10-1 2 -11-1 1-12- -13- -14- Plan Do Check Action Check Action 1 -15- -16- -17- -18- -19- -20- -21- -22- 10 2 9 3 9 2 1 10 2 9 3 6 4 1 6 6 10 2 10 2 11 1 8 1 8 4
Nikon アニュアルレポート 2000
2000 1999 2000 371,801 305,765 $ 3,503 21.6% 18,434 ( 8,741) 174 7,770 (18,233) 73 21.01 (49.29) $ 0.20 5.00 3.00 0.05 66.7% 502,175 474,965 $ 4,731 5.7% 166,495 160,991 1,568 3.4% 1 2 3 4 5 6 NSR-S204B
010_9553901302406.indd
2011 WDB REPORT CONTENTS 1 WDB Holdings co.,ltd. Annual Report 2011 2 WDB Holdings co.,ltd. Annual Report 2011 3 WDB Holdings co.,ltd. Annual Report 2011 4 WDB Holdings co.,ltd. Annual Report 2011 5 WDB
& IT/ IT
C O R P O R A T E O U T L I N E 2 8 &-3 25 9 1 1 IT/7 1 2 3 4 6 8 1 11 12 13 14 16 2 21 22 IT 24 25 28 32 34 36 37 38 39 4 41 42 43 44 45 46 &HLDGS. &HLDGS. &HLDGS.1 35, 13, 2,8 1,4 76 97 69-6 7 3 2 2
1963 1 2 8 12 18 20 22 23 24 6 25 30 54 55
2007 1963 1 2 8 12 18 20 22 23 24 6 25 30 54 55 200720063 2007 2006 2007/2006 2007. 118,139 105,408 12.1% $1,000,754 56,344 46,405 21.4 477,289 32,796 31,502 4.1 277,813 11,836 10,085 17.4 100,267 4,333
The Chain of Choice FC2008 FC Q&A Being the Chain of Choice for Franchise Owners FC FC Q A CSR
Our Overriding Goal 2008 2008 2 01 02 03 04 12 The Chain of Choice FC2008 FC Q&A Being the Chain of Choice for Franchise Owners FC 18 21 22 24 26 27 71 72 73 2008FC Q A CSR The Chain of Choice FC CVS FC
?? 1 DTU
?? 1 DTU-1031 1 2 B VCCI-B Wacom TM Version 1.0, C0413 Copyright Wacom Co., Ltd., 2013 2 3 3 4 5 6 7 8 9 10 10 10 11 11 1 12 2 13 13 14 15 15 16 16 16 17 17 18 19 19 19 20 20 21 23 24 24 25 26 27 28 32
1120再入稿_Ushio_ウシオ電機_53中期_株主通信.indd
PRISM 2015 4 12015 9 30 2015 12 CONTENTS USHIO NOW! P 2 P 4 P 6 P 8 P10 P12 P14 USHIO NOW! 1964 No. 1 1964 3 19,556 2015 9 30 5,764 1,749 853 3,162 2015 4 12015 9 30 886 441 387 479 20 65 4 5 2 USHIO NOW!
ニコンレポート2017
NIKON REPORT 217 217 217 3 Unlock the future with the power of light 217 7 251 1 1 1 217216 11 Unlock the future with the power of light 2 NIKON REPORT 217 BUSINESS STRATEGY 2 3 8 CFO 1 1 12 FAQ 13 TOPICS
1 20 2 26 4 28 6 30 10 32 12 33 14 74 75 1 2 0 6,000 7,000 5,000 4,000 3,000 2,000 1,000 2015 2012 2013 500 600 700 400 300 200 100 0 10 12 14 8 6 4 2 2015 2012 2013 2014 6,016 2014 6,252 2016 7.1 8.7
日本興亜損保の現状２００８
28 1 NIPPONKOA INSURANCE CONTENTS introduction NIPPONKOA INSURANCE 2 NIPPONKOA INSURANCE 3 NIPPONKOA INSURANCE NIPPONKOA INSURANCE 4 introduction 5 NIPPONKOA INSURANCE NIPPONKOA INSURANCE 6 introduction
平成18年版 男女共同参画白書
i ii iii iv v vi vii viii ix 3 4 5 6 7 8 9 Column 10 11 12 13 14 15 Column 16 17 18 19 20 21 22 23 24 25 26 Column 27 28 29 30 Column 31 32 33 34 35 36 Column 37 Column 38 39 40 Column 41 42 43 44 45
Vision and Strategy IP 1 Fields: An Evolving History 5 9 11 Performance 17 18 At a Glance 20123 18 19 19 22 25 Sustainability CSR 27 32 Financial Sect
We Make It Happen 2012 2011412012 331 Vision and Strategy IP 1 Fields: An Evolving History 5 9 11 Performance 17 18 At a Glance 20123 18 19 19 22 25 Sustainability CSR 27 32 Financial Section 39 49 51
III
III 1 1 2 1 2 3 1 3 4 1 3 1 4 1 3 2 4 1 3 3 6 1 4 6 1 4 1 6 1 4 2 8 1 4 3 9 1 5 10 1 5 1 10 1 5 2 12 1 5 3 12 1 5 4 13 1 6 15 2 1 18 2 1 1 18 2 1 2 19 2 2 20 2 3 22 2 3 1 22 2 3 2 24 2 4 25 2 4 1 25 2
iii iv v vi vii viii ix 1 1-1 1-2 1-3 2 2-1 3 3-1 3-2 3-3 3-4 4 4-1 4-2 5 5-1 5-2 5-3 5-4 5-5 5-6 5-7 6 6-1 6-2 6-3 6-4 6-5 6 6-1 6-2 6-3 6-4 6-5 7 7-1 7-2 7-3 7-4 7-5 7-6 7-7 7-8 7-9 7-10 7-11 8 8-1
アニュアルレポート２００３
..................................... 1............................. 2 6 8 10 12 14............................ 16..................... 20.............................. 21.........................................
26 1. 2. 3. 4. 5. Annual Report 26 1 C o n t e n t s... 2... 3 Growth Action 21... 4... 6... 11 At a Glance... 12... 14... 31... 32... 34... 35... 36 CSR... 38... 4... 41... 72... 74... 75 2 3 311 * 26
NNA Since 1989
NNA Since 1989 NNA 2011 1945 NHK 17 1 9 199578 1 1989 8 2016 4 7,000 1 2017 19.5 189 UFJ NNA JAPAN CO., LTD. 1989 8 WIN HONEST PLANNING LIMITED 1992 6 1994 9 1995 4 6 8 1996 8 10 1998 1 4 WebNNA PLUS 1999
...j.N.. AR2005(.O..)
1984 expansion 1998 world 2001 2005 transformation FAST RETAILING CO., LTD. our group UNIQLO COMPTOIR DES COTONNIERS FOOT PARK ASPESI national standard Theory business model products Do you know?
2 1 B VCCI-B Cintiq Wacom Adobe Adobe Photoshop Microsoft Windows Apple Apple Mac TM Cintiq 13HD Version 1.0, Rev C Wacom Co., Ltd. All right
1 Cintiq 13HD DTK-1300 1 2 1 B VCCI-B Cintiq Wacom Adobe Adobe Photoshop Microsoft Windows Apple Apple Mac TM Cintiq 13HD Version 1.0, Rev C0413 2013 Wacom Co., Ltd. All rights reserved. 2 Contents Index
untitled
CONTENTS 1 2 4 6 8 10 11 12 14 15 16 17 18 19 20 21 22 23 24 27 28 29 30 31 32 33 Top Message 2 Daifuku Co., Ltd. CSR Report 2010 Daifuku Co., Ltd. CSR Report 2010 3 4 Daifuku Co., Ltd. CSR Report 2010
年 3 月期
214 214 年 3 月期 1 巻頭特集 6 6 年間の主要財務指標 8 株主の皆様へ 12 特集グローバルサプライチェーン構築の取り組み モダニゼーション事業の状況 16 営業概況 25 CSR 28 コーポレート ガバナンス 3 取締役 監査役 執行役員 32 財務セクション 33 財政状態および経営成績の検討と分析 36 連結貸借対照表 38 連結損益計算書 39 連結包括利益計算書 4 連結株主資本等変動計算書
大和ハウスグループ アニュアルレポート２００６
Heart goes on 26 Contents 1 8 1 14 16 18 Vision 24 3 36 4 41 43 44 Commitment 58 Action 73 14 16 19 136 anywhere 2 Daiwa House Group anytime 3 anyone 5 We Build Hearts 8 Daiwa House Group Dear Stakeholders
IT /
Corporate Outline 212 1 2 3 4 6 9 1 11 12 13 15 16 18 22 23 24 IT / 26 28 32 36 38 4 41 42 43 44 45 &HLDGS. &HLDGS. 46,6 15,6 &HLDGS.1 4,8 1,7 プロフィール 185 164 196-188 1,64 8 5 2 4 2 3-14,5 173 176 26 486-469
100 3 100 Contents 2 4 6 8 12 UA 16 3 17 18 EC 20 22 24 26 30 32 38 5 44 11 46 2017 2017 IIRC 4 13 31 2017 3 IR www.united-arrows.co.jp/ir/lib/index.html P38 5 2 3 1 2 3 VISION VOICE VISUAL 1989 1995 2001
アニュアルレポート2004
1 2 6 6 8 10 12 14 16 18 18 20 22 28 30 31 32 33 44 45 46 48 49 2004 2003 2002 2001 2000 2004 2004/2003 191,939 167,942 174,218 242,726 174,812 $1,810,745 14.3% 9,600 3,225 140 23,903 (4,628) 90,566 197.7
Kyowa_本文.indd
2009 200810 5 9 11 13 14 19 21 39 1 2009 ................................................... 3 5 7.................. 9................ 10 2009 20097 P8 2008 Biokyowa 200941 20082008420093 200820081 122009
1.... 1 1.1...1 1.2...2 2.... 3 2.1...3 2.2...3 2.3...4 2.4...5 3.... 6 3.1...6 3.2...19 3.3...20 4.... 22 4.1...22 4.2...23 4.3...23 4.4...24 4.5...34 4.6...34 4.7 PDCA...35 1. 1.1 2 261 46 26 JR 17 1
C O N T E N T S
ALL NIPPON AIRWAYS CO., LTD. 2003 Fifty Years of Progress in Air Transportation C O N T E N T S Focused on the Next 50 Years 50 1 2 3 Q1 A1 4 Focused on the Next 50 Years 5 Q2 A2 6 Focused on the Next
1
ユニシャトル HP 1 2 3 4 5 5.5m 2.5m 20m 6 http://www.muratec.jp http://www.murata-system.co.jp Logistics & Automation Division http://www.muratec.co.jp MURATA MACHINERY, LTD. International Business Dept. Green-Bldg.
Channel to Discovery Plan &
2007 Channel to Discovery Plan & 3 2007 3 2008 1 1 2 6 8 2006 10 14 1 2 16 19 20 22 24 26 28 30 32 34 36 42 43 44 45 70 71 72 2000 10 1 2007 2 2007 2000 10 3 2010 M 2007 M 2010 1,000 2006 2006 M&A 102006
ONLINE_MANUAL
JPN ii iii iv v 6 vi vii viii 1 CHAPTER 1-1 1 2 1-2 1 2 3 4 5 1-3 6 7 1-4 2 CHAPTER 2-1 2-2 2-3 1 2 3 4 5 2-4 6 7 8 2-5 9 10 2-6 11 2-7 1 2 2-8 3 (A) 4 5 6 2-9 1 2-10 2 3 2-11 4 5 2-12 1 2 2-13 3 4 5
ONLINE_MANUAL
JPN ii iii iv v vi 6 vii viii 1 CHAPTER 1-1 1 2 1-2 1 2 3 1-3 4 5 6 7 1-4 2 CHAPTER 2-1 2-2 2-3 1 2 3 4 5 2-4 6 7 8 2-5 9 10 2-6 11 2-7 1 2 2-8 3 (A) 4 5 6 2-9 1 2-10 2 3 2-11 4 5 2-12 1 2 2-13 3 4 5
AccessflÌfl—−ÇŠš1
ACCESS ACCESS i ii ACCESS iii iv ACCESS v vi ACCESS CONTENTS ACCESS CONTENTS ACCESS 1 ACCESS 1 2 ACCESS 3 1 4 ACCESS 5 1 6 ACCESS 7 1 8 9 ACCESS 10 1 ACCESS 11 1 12 ACCESS 13 1 14 ACCESS 15 1 v 16 ACCESS
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
untitled
High Performance Mass Flow Controller 45 45 s G H T W I A B C D E F G T D W I F E H+6 H SEC SEF -Z512KX SEC SEF -Z512 MG X SEC SEF -Z522 MG XN SEC SEF -Z532MGX N SEC SEF -Z542MGX N SEC SEF -Z552MGX
2013BR_cover2_f
41331 3 331 3 Business Report 212.4.1 213.3.31 33193 6727 168-63 84 41 41 12-782-31 http://www.smtb.jp/personal/agency/index.html IR http://www.wacom.com/jp/ja/investors 349-114811 TEL48-78-1211FAX48-78-122
™…
i 1 1 1 2 3 5 5 6 7 9 10 11 13 13 14 15 15 16 17 18 20 20 20 21 22 ii CONTENTS 23 24 26 27 2 31 31 32 32 33 34 37 37 38 39 39 40 42 42 43 44 45 48 50 51 51 iii 54 57 58 60 60 62 64 64 67 69 70 iv 70 71
OVERVIEW Our Sustainability ALSOK 1 ALSOK 1 P P.12 3 P.26 4 ALSOK 8 P.9
CSR REPORT 2013 CSR 2013 2331 OVERVIEW Our Sustainability ALSOK 1 ALSOK 1 P.10 2 7 2 P.12 3 P.26 4 ALSOK 8 P.9 ALSOK ALSOK CSR 5 P.8 6 6 P.19 7 3 4 P.18 5 8 P.20 ALSOK CSR Report 2013 1 OVERVIEW Our Corporate